Peptides are everywhere right now. Chances are, someone in your life has already mentioned them — and if they haven't, they will.

Maybe a friend has been injecting something into his shoulder and swears it's a miracle cure. Or a colleague said she heard about BPC-157 on a podcast and isn't sure what to think. Either way, most of the information circulating sits at one of two unhelpful poles: breathless enthusiasm on one side, reflexive dismissal on the other.

Neither is helpful.

And in a space where the excitement is FAR outpacing regulation, the most valuable thing you can bring to that conversation is the right set of questions.

A brief and genuinely fascinating history

For most of human history, medicine came from the natural world — plants, fungi, roots. Statins trace their origins to red yeast rice, a fermented grain used in traditional Chinese medicine for centuries before researchers isolated the active compound.[1]

But over the last 150 years or so, scientists have been looking somewhere new: inside the cells of animals.

Ivan Pavlov understood something of this many years ago. We remember him for the dogs and the bell — but Pavlov's lab studied stomach juices so extensively that he even bottled and sold extracted gastric acids as a treatment for human indigestion! The observation that something in those juices could heal planted a seed that, decades later, a research group in Croatia would pick up [2] - more on that in a moment.

GLP-1 medications were first discovered in the 1980s, researchers identified GLP-1 as a gut hormone that regulated blood sugar and appetite, but it broke down in the bloodstream within minutes. The breakthrough came from a Gila monster: a venomous lizard native to the American Southwest whose saliva contained a compound structurally similar to human GLP-1, but far more stable. Scientists synthesized it, refined it across decades of rigorous clinical trials, and produced the drugs we now know as Ozempic and Wegovy.[3]

A desert lizard. Decades of research. One of the most consequential drug classes in modern medicine. That's the kind of journey that earns a seat at the table.

But peptides are not new...they're short chains of amino acids...think of them as text messages between your cells. Your body is already fluent in this language, running on peptides constantly and quietly. Here are just a few peptides you'll instantly recognize:

• Insulin — regulates blood sugar
• Oxytocin — connection and trust
• Endorphins — your natural pain relief
• Growth hormone — repair and recovery
• GLP-1 — appetite, blood sugar, metabolic function

Almost every organ produces its own signature of them. This is exactly what makes this space so compelling — and precisely why it requires such careful thinking.

Why success stories do NOT simply transfer

Insulin's story is worth highlighting....when Frederick Banting and Charles Best isolated it in 1921 and administered it to a dying 14-year-old boy, his blood sugar fell within 24 hours and he made a full recovery. It was one of the most significant medical breakthroughs of the 20th century — and it was a peptide.[4]

More recently, semaglutide emerged from decades of rigorous clinical investigation and large-scale outcome trials across tens of thousands of patients — demonstrating significant weight loss and meaningful improvements in metabolic markers for those who remain on it.[5]

So yes. Some peptides are extraordinary. But their success doesn't transfer to the rest of the category.

Here's what those two examples actually teach us:

• Every peptide that has earned our trust went through a long, rigorous process: human trials, independent safety monitoring, outcome data reviewed by a body with no financial stake in the result.
• The GLP-1s are NOT evidence that all peptides work. 
• GLP-1s cleared a very high bar. That bar exists for a reason.
• Most of what's circulating in the grey-market wellness world right now has not come close to clearing it.

Why peptides are having a moment

Why now? I believe it's due to several forces converging at once: frustration with a medical system that manages disease rather than restoring health; GLP-1s normalized self-injection, and a post-COVID surge of people taking their health into their own hands.

I understand the appeal. But many peptides being marketed today are not FDA approved, quality control varies enormously by source.

Health information moves faster than health evidence — so being discerning about what you put into your body has never mattered more.

"Not FDA approved" — what does that really imply?

"Not FDA approved" means that the full burden of inquiry falls on you. FDA approval means a compound has been tested in humans for a specific purpose, with safety and efficacy data reviewed by an independent body — so we know, with reasonable confidence, what it does, at what dose, and for whom. When that foundation doesn't exist, those questions don't disappear. They simply become yours to answer.

Key questions to ask include

Is there a credible mechanism of action? This means a defined, plausible chain of steps from target engagement to intended effect — not a vague claim. "Boosts cellular energy" is not a mechanism. "B vitamins support ATP production via their role as coenzymes in the Krebs cycle and electron transport chain" — that's a mechanism. One is marketing. The other is biology you can evaluate. When a mechanism is absent or genuinely unclear, that's the first sign additional caution is warranted.

What do we know about safety and dosing in humans? Animal data can suggest. Cell culture data can hint. But neither tells you what happens in a living human body, at what dose, over what time period. The same compound that may be helpful at one dose can be inert or harmful at another. Without human trials, the therapeutic dose is unknown.

Is there evidence of actual outcomes in humans — not just biomarkers? This distinction matters enormously. A peptide that raises growth hormone levels in a short study has shown a biomarker moving. That is not the same as demonstrating improved muscle mass, better recovery, reduced fat, or longer life. A shift in a biomarker is a starting point. It is not a result.

Do the potential benefits outweigh the risks as currently understood? This calculation shifts entirely depending on context. The risk-benefit assessment for someone with a severe rare disease looks very different from the one for an otherwise healthy person seeking a performance edge. Who the compound was studied in matters as much as whether it was studied at all.

Is there an approved alternative that addresses the same goal? If a legitimate, regulated option already exists for what you're trying to achieve, that's worth knowing before you proceed.

A case study in asking the right questions: BPC-157

BPC-157 is the peptide that illustrates almost everything worth understanding about this space.

BPC stands for Body Protection Compound. It's a synthetic 15-amino-acid peptide, created in a lab by a research group in Croatia in the early 1990s, inspired by that same thread of observation — Pavlov's gastric juices, the idea that something in the stomach environment could heal [6].

The animal studies on BPC-157 are genuinely intriguing: severe tendon injuries, burns, gut damage — results that attracted real scientific curiosity. And the stories that followed are compelling. Which brings me to 'anecdata' aka 'stories' dressed up to sound like evidence! Someone recovered from an injury and credits a peptide. But what else was happening? What would have happened without it? We can't know. That's exactly what a randomized controlled trial is designed to answer — and BPC-157 doesn't have one. Not a single completed, peer-reviewed RCT in humans, from any independent research group.[7]

Virtually all published data on BPC-157 comes from the same Croatian research cluster — the group connected to the patents, to a registered clinical trial that has produced no results in over a decade, and to the company whose only drug candidate is BPC-157 itself. When the entire evidence base comes from one source with a financial stake in the outcome, that's not a minor caveat.  It's a foundational one!

Run it through the five questions and here's what you find: no officially confirmed mechanism, no human safety data, no outcome data. The science is genuinely exciting, but it's also very early. Which is exactly why the questions matter — right now, the stories are running well ahead of the evidence.

Buyer beware

Here's something that surprises most people too: virtually all peptide raw materials — from compounding pharmacies to grey-market vials — originate from the same place. China. The difference between sources isn't the origin. It's the level of oversight applied after that. Think of it as a spectrum:

• Compounding pharmacies operate under state pharmacy board oversight and are subject to inspection — but they vary considerably in rigor, and they all start from the same upstream supply chain.
• "Research use only" vendors have essentially no manufacturing oversight. Quality ranges from excellent to dreadful, and can vary batch to batch from the same supplier.
• The grey market proper carries all of the above risks, plus unknown handling, storage, and reconstitution conditions.

And, FYI - US customs data shows imports of hormone and peptide compounds from China reached $328 million in Q1 -Q3 '25 — nearly double the same period the year before, through one border, in declared shipments only.[9] The FDA warns of serious safety risks from potential impurities, and independent testing suggests around 8% of products sampled could be contaminated. Third-party testing can confirm purity — but not sterility, endotoxin levels, or stability after reconstitution.

Caveat emptor has never felt more apt. Know what to ask. Work with a trusted physician. Know this landscape. Then decide.

Another key question: What do you hope to address?

I was at a dinner party recently where a woman was raving about BPC-157 injections in her knee — said they'd worked wonders for knee issues she'd had for years. It was only later in the conversation that she mentioned she was still struggling with IBS symptoms that had plagued her for as long as she could remember.

I asked if anyone had ever suggested the two might share a common driver. She looked at me blankly.

That moment stayed with me. Because the real question was never which peptide to try. It was: what's actually driving the inflammation? And had anyone ever looked?

This is where the B.I.G.3 — Blood Sugar, Inflammation, Gut Health™ — becomes the most important framework in the room.

A compromised gut impairs absorption, drives systemic inflammation, and undermines the very healing pathways peptides are meant to support. Blood sugar dysregulation amplifies inflammatory signaling and disrupts recovery. Chronic, low-grade inflammation is the environment in which most of the conditions people hope to bio-hack their way out of take root.

Here's the truth most people skip over:

• You don't need a growth peptide if you're chronically sleep-deprived
• You don't need a repair peptide if you're not eating adequate protein
• You don't need a regenerative intervention if inflammation is still uncontrolled

Adding more signals into a chaotic, inflamed, insulin-resistant system seems like an easy answer, but it most likely just creates more 'noise'.

The unsexy answer — and why it's still the right one

I get it. Working on food choices, daily movement, sleep, and stress isn't glamorous. It never has been. It requires consistency, patience, and the willingness to make changes that don't produce Instagram-worthy results on day three. An injection is infinitely more appealing — faster, more decisive, and easier to attribute results to.

But if you want sustainable change that you own — that doesn't depend on an exogenous substance, a compounding pharmacy, or a grey-market vial — then a solid foundation is what you need. 

When the foundation is solid — blood sugar stable, gut integrity restored, inflammation addressed, muscle built, sleep protected — targeted therapies can potentially add something meaningful on top of all of that. The signal underneath them is clear, and there's something worth amplifying. But when the foundation is shaky, you're not compounding gains. You're potentially adding complexity to instability.

Peptides amplify the biological environment you already have. Build that environment first.

Some people need to approach this space with additional care:

• Anyone with active cancer, a history of cancer, or a hormone-sensitive condition
• Anyone with an autoimmune disease
• Anyone considering peptides for purely cosmetic purposes
• Anyone buying from unregulated online sources without physician involvement
• Anyone who hasn't yet addressed the fundamentals of sleep, nutrition, blood sugar, and gut health

And for everyone else: work with a qualified physician who can order appropriate labs, monitor your progress, and be held accountable. The difference between a thoughtful clinical conversation and buying vials from the internet based on a TikTok is not a small one.

The bottom line

Peptides may represent a genuinely exciting frontier in medicine. Some of them, properly studied and appropriately prescribed, may well turn out to be extraordinary additions to the clinical toolkit. The science is moving FAST, and the landscape will look different in five months, whatever about years, than it does today.

But right now, with the evidence we actually have, the most powerful thing you can do is build the biological terrain that allows your body to respond well to any input — including, one day, perhaps the right peptide at the right time for the right reason (with the right supervision from a knowledgeable, and above board, licensed physician).

I'll leave you with this: I'm peptide curious — with copious amounts of caution. And I hope that after reading this, you feel better equipped to be curious too. Not recklessly. Not fearfully. But with the right questions in hand.

So before you ask which peptide should I take, ask the better question: have I built the foundation?

Because that foundation is always the future of your health.

TL;DR

• Success stories don't automatically transfer. Insulin and GLP-1s are peptides that earned their place through decades of rigorous science. 
• "Not FDA approved" shifts the full burden of inquiry to you — and in a world where marketing moves faster than evidence, that matters.
• Key questions to ask of any peptide: Is there a credible mechanism? What do we know about safety and dosing in humans? Is there evidence of outcomes — not just biomarkers? Do benefits outweigh risks? Is there an approved alternative?
• BPC-157 is the case study worth knowing. Intriguing animal data, a single research group in Croatia, no completed human RCTs.
• Compelling 'anecdata' is not the same as evidence.
• The grey market runs on Chinese raw materials — at every tier. Compounding pharmacies, research-use-only vendors, and grey-market sources all start from the same upstream supply chain. Stringency and consistency vary enormously.
• Functional medicine asks first: what are we trying to address? And whether the foundations — blood sugar, inflammation, gut integrity — have been properly tended before adding anything on top.
• Peptides amplify the biological environment you already have. Build that environment first. Longevity isn't built from hacks. It's built from habits.

References

[1] Endo A. The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research. 1992;33(11):1569–82.

[2] Pavlov IP. The Work of the Digestive Glands. London: Charles Griffin & Company, 1902.

[3] Eng J. Discovery of exendin-4, a GLP-1 receptor agonist derived from Gila monster venom. Regulatory Peptides. 1992. See also: "From Lizard Venom to Billion-Dollar Drug: 30 Years of GLP-1." Molecular Weights. April 2026.

[4] Banting FG, Best CH. The internal secretion of the pancreas. Journal of Laboratory and Clinical Medicine. 1922.

[5] Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.

[6] Sikiric P, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology. 1994.

[7] Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185.

[8] Sun J. "Peptides and the pursuit of the perfect body." The New York Times. January 2026.

[9] The Week. "The regulation issues with grey-market peptides." April 14, 2026.